$DYN insider trading
Over the last 12 months, Dyne Therapeutics insiders reported 6 buys totaling $232K and 31 sales totaling $168.2M across SEC Form 4 filings. 81% of those filings were made under pre-arranged 10b5-1 trading plans.
- Bought · 12m
- $232K 6 events
- Sold · 12m
- $168.2M 31 events
- Events · 12m
- 37 Form 4 filings, grouped
- Insiders · 12m
- 7 distinct reporters
- 10b5-1 share
- 81% of events, not dollars
All insider trades
Scroll the table sideways for price, value and marks.
| Date | Insider | Type | Shares | Avg price | Value | Δ stake | Marks |
|---|---|---|---|---|---|---|---|
| Aug 14, 2026 | Rhodes Jason PD | ▼ Sale | 2,586,928 | $25.2 | $65.2M | -85.8% | plan · 6 tranches · indirect |
| Aug 13, 2026 | Friedl-Naderer JohannaChief Commercial Officer · O | ▼ Sale | 226 | $26.28 | $6K | -0.1% | plan |
| Aug 13, 2026 | Kerr DouglasChief Medical Officer · O | ▼ Sale | 1,556 | $26.28 | $41K | -0.9% | plan |
| Aug 13, 2026 | Cox JohnCEO & President · O·D | ▼ Sale | 4,986 | $26.28 | $131K | -1.4% | plan |
| Aug 13, 2026 | Lucera ErickChief Financial Officer · O | ▼ Sale | 1,797 | $26.28 | $47K | -1.5% | plan |
| Jul 27, 2026 | Kersten DirkD | ▼ Sale | 261,460 | $25.51 | $6.7M | -6.8% | plan · 2 tranches · indirect |
| Jul 7, 2026 | Rhodes Jason PD | ▼ Sale | 777,451 | $22.97 | $17.9M | -99.6% | plan · 10 tranches · indirect |
| Jun 29, 2026 | Rhodes Jason PD | ▼ Sale | 504,695 | $21.23 | $10.7M | -34.1% | plan · 6 tranches · indirect |
| Jun 25, 2026 | Lucera ErickChief Financial Officer · O | ▼ Sale | 2,362 | $20.37 | $48K | -1.9% | — |
| Jun 25, 2026 | Rhodes Jason PD | ▼ Sale | 267,760 | $21.09 | $5.6M | -19.9% | plan · 9 tranches · indirect |
| Jun 23, 2026 | Kersten DirkD | ▼ Sale | 263,962 | $20.7 | $5.5M | -6.4% | plan · 3 tranches · indirect |
| Jun 18, 2026 | Kersten DirkD | ▼ Sale | 84,355 | $20.1 | $1.7M | -2% | plan · 2 tranches · indirect |
| Jun 16, 2026 | Friedl-Naderer JohannaChief Commercial Officer · O | ▼ Sale | 145 | $18.33 | $3K | -0.1% | plan |
| Jun 16, 2026 | Kerr DouglasChief Medical Officer · O | ▼ Sale | 887 | $18.33 | $16K | -0.5% | plan |
| Jun 16, 2026 | Cox JohnCEO & President · O·D | ▼ Sale | 2,683 | $18.33 | $49K | -0.7% | plan |
| Jun 8, 2026 | Posner Brian SD | ▲ Buy | 2,000 | $16.94 | $34K | +8.9% | — |
| Jun 3, 2026 | Posner Brian SD | ▲ Buy | 2,500 | $17.48 | $44K | +12.5% | — |
| May 26, 2026 | Posner Brian SD | ▲ Buy | 2,000 | $18.21 | $36K | +11.1% | — |
| May 6, 2026 | Rhodes Jason PD | ▼ Sale | 106,723 | $18.14 | $1.9M | -8.6% | plan · 12 tranches · indirect |
| Apr 28, 2026 | Rhodes Jason PD | ▼ Sale | 227,337 | $18.38 | $4.2M | -16.4% | plan · 8 tranches · indirect |
| Apr 27, 2026 | Rhodes Jason PD | ▼ Sale | 384,549 | $18.47 | $7.1M | -24.2% | plan · 12 tranches · indirect |
| Apr 22, 2026 | Kersten DirkD | ▼ Sale | 10,952 | $20.01 | $219K | -0.3% | plan · 2 tranches · indirect |
| Apr 22, 2026 | Rhodes Jason PD | ▼ Sale | 834,302 | $19.75 | $16.5M | -39.4% | plan · 16 tranches · indirect |
| Apr 20, 2026 | Kersten DirkD | ▼ Sale | 337,248 | $20.21 | $6.8M | -7.4% | plan · 2 tranches · indirect |
| Apr 16, 2026 | Kersten DirkD | ▼ Sale | 99,613 | $20.35 | $2.0M | -2.1% | plan · 3 tranches · indirect |
| Apr 1, 2026 | Lucera ErickChief Financial Officer · O | ▼ Sale | 5,727 | $18.64 | $107K | -4.4% | plan |
| Mar 30, 2026 | Posner Brian SD | ▲ Buy | 2,000 | $17.08 | $34K | +14.8% | — |
| Mar 11, 2026 | Posner Brian SD | ▲ Buy | 2,000 | $19.35 | $39K | +17.4% | — |
| Mar 11, 2026 | Kersten DirkD | ▼ Sale | 129,672 | $19.52 | $2.5M | -2.7% | plan · indirect |
| Mar 10, 2026 | Kersten DirkD | ▼ Sale | 688,788 | $19.09 | $13.1M | -12.6% | plan · 4 tranches · indirect |
| Mar 6, 2026 | Posner Brian SD | ▲ Buy | 3,000 | $15.06 | $45K | +35.3% | — |
| Mar 5, 2026 | Friedl-Naderer JohannaChief Commercial Officer · O | ▼ Sale | 148 | $14.9 | $2K | -0.1% | plan |
| Mar 5, 2026 | Kerr DouglasChief Medical Officer · O | ▼ Sale | 904 | $14.9 | $13K | -0.5% | plan |
| Mar 5, 2026 | Cox JohnCEO & President · O·D | ▼ Sale | 2,732 | $14.9 | $41K | -0.7% | plan |
| Dec 5, 2025 | Cox JohnCEO & President · O·D | ▼ Sale | 2,662 | $20.72 | $55K | -1.3% | plan |
| Dec 5, 2025 | Kerr DouglasChief Medical Officer · O | ▼ Sale | 880 | $20.72 | $18K | -1% | plan |
| Dec 5, 2025 | Friedl-Naderer JohannaChief Commercial Officer · O | ▼ Sale | 144 | $20.72 | $3K | -0.2% | plan |
| Sep 5, 2025 | Cox JohnCEO & President · O·D | ▼ Sale | 2,640 | $13.41 | $35K | -1.3% | plan |
| Sep 5, 2025 | Friedl-Naderer JohannaChief Commercial Officer · O | ▼ Sale | 1,038 | $13.29 | $14K | -1.1% | plan · 2 tranches |
| Sep 5, 2025 | Kerr DouglasChief Medical Officer · O | ▼ Sale | 4,425 | $13.3 | $59K | -4.8% | plan · 2 tranches |
Every $DYN filing on this page is one API call away
The same Form 4 data over REST or MCP, already grouped into events with the plan flag and the dollar value read. A free key does 100 calls a day and needs no card. Prefer email? Dyne Therapeutics filings can reach your inbox instead.
Corporate insiders — officers, directors and 10%+ owners — must report their trades to the SEC on Form 4 within two business days. This page shows open-market activity: purchases (code P), sales (S) and dispositions back to the issuer (D). Scheduled compensation events such as stock grants and option exercises are also filed on Form 4 but carry no trading signal, so they are not shown and counts here can be lower than the raw EDGAR filing total. We group each filing's transactions into one economic event (a laddered 10b5-1 sale is one event, not 25 rows), flag pre-arranged plans and late filings, and link every event to its AI-scored article in the $DYN feed.